WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005063712) 5-HT2 RECEPTORS MODULATORS, THEIR PHARMACEUTICALS COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR AND MUSCLE DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/063712    International Application No.:    PCT/US2004/042921
Publication Date: 14.07.2005 International Filing Date: 21.12.2004
IPC:
C07D 215/42 (2006.01), C07D 495/04 (2006.01)
Applicants: MYOGEN, INC. [US/US]; 7575 W. 103rd Avenue, Suite 102, Westminster, CO 80021-5426 (US) (For All Designated States Except US).
BUSH, Erik [US/US]; (US) (For US Only).
MELVIN, Larry [US/US]; (US) (For US Only)
Inventors: BUSH, Erik; (US).
MELVIN, Larry; (US)
Agent: HIGHLANDER, Steven, L.; Fulbright & Jaworski, LLP, Suite 2400, 600 Congress Avenue, Austin, TX 78701 (US)
Priority Data:
60/531,854 23.12.2003 US
Title (EN) 5-HT2 RECEPTORS MODULATORS, THEIR PHARMACEUTICALS COMPOSITIONS AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR AND MUSCLE DISEASES
(FR) MODULATEURS DE RECEPTEURS 5-HT2, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES ET MUSCULAIRES
Abstract: front page image
(EN)The present invention provides certain compounds, pharmaceutical formulations thereof, and methods for the treatment of conditions mediated by 5-HT2 receptors. These compounds provide for modulation of the signals mediated by 5-HT2 receptors, specifically those receptors in the cardiovascular system. Thus, these compounds may be used alone or in conjunction with other drugs to treat cardiovascular diseases such as, but not limited to, muscle atrophy, cardiac hypertrophy, heart failure, and primary pulmonary hypertension.
(FR)La présente invention a trait à certains composés, leurs formulations pharmaceutiques, et des procédés pour le traitement de conditions liées aux récepteurs 5-HT2. Ces composés assurent la modulation des signaux transmis par l'intermédiaires des récepteurs 5-HT2, plus spécifiquement ces récepteurs se trouvant dans le système cardio-vasculaire. Ainsi, ces composés peuvent être utilisés seuls ou en combinaison avec d'autres médicaments pour le traitement de maladies cardio-vasculaires, telles que, mais de manière non exclusive, l'atrophie musculaire, l'hypertrophie cardiaque, et l'hypertension pulmonaire primaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)